You just read:

Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007

News provided by

Quark Pharmaceuticals, Inc.

Oct 20, 2010, 10:25 ET